Integra LifeSciences (NASDAQ:IART – Get Free Report) issued an update on its third quarter 2024 earnings guidance on Monday morning. The company provided earnings per share guidance of 0.360-0.440 for the period, compared to the consensus earnings per share estimate of 0.850. The company issued revenue guidance of $372.0 million-$382.0 million, compared to the consensus revenue estimate of $432.1 million. Integra LifeSciences also updated its FY 2024 guidance to 2.410-2.570 EPS.
Integra LifeSciences Stock Down 19.1 %
Shares of NASDAQ:IART opened at $25.42 on Tuesday. Integra LifeSciences has a 1-year low of $22.36 and a 1-year high of $46.09. The company has a debt-to-equity ratio of 1.15, a current ratio of 4.68 and a quick ratio of 3.35. The stock has a market cap of $2.00 billion, a P/E ratio of 50.84, a P/E/G ratio of 1.14 and a beta of 1.11. The firm has a fifty day moving average price of $29.72 and a 200 day moving average price of $33.65.
Integra LifeSciences (NASDAQ:IART – Get Free Report) last released its earnings results on Monday, May 6th. The life sciences company reported $0.55 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.55. Integra LifeSciences had a return on equity of 14.27% and a net margin of 2.63%. The business had revenue of $368.90 million for the quarter, compared to analyst estimates of $361.96 million. During the same quarter in the previous year, the company posted $0.74 earnings per share. The company’s revenue for the quarter was down 3.2% compared to the same quarter last year. Sell-side analysts predict that Integra LifeSciences will post 3.03 EPS for the current year.
Wall Street Analyst Weigh In
Check Out Our Latest Stock Analysis on Integra LifeSciences
Insider Activity at Integra LifeSciences
In other Integra LifeSciences news, Chairman Stuart Essig bought 52,641 shares of the business’s stock in a transaction on Thursday, May 23rd. The stock was bought at an average price of $28.49 per share, for a total transaction of $1,499,742.09. Following the completion of the transaction, the chairman now owns 487,922 shares in the company, valued at approximately $13,900,897.78. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 3.10% of the stock is currently owned by company insiders.
Integra LifeSciences Company Profile
Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.
Featured Articles
- Five stocks we like better than Integra LifeSciences
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- Top 2 Cheap Healthcare Stocks to Buy as Sector Outperforms
- How to Calculate Retirement Income: MarketBeat’s Calculator
- Healthcare Stock Rides the Acute Services Phenomenon to New Highs
- High Dividend REITs: Are They an Ideal Way to Diversify?
- Leading Oil Refiner’s Stock Climbs Despite Market Volatility
Receive News & Ratings for Integra LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.